Kinase Inhibitor class drugs
34 results
Alecensa (alectinib hydrochloride)
(ALECTINIB HYDROCHLORIDE)Genentech, Inc.
Usage: ALECENSA is indicated for adjuvant treatment of resected ALK-positive non-small cell lung cancer (NSCLC) in adults and for the treatment of metastatic ALK-positive NSCLC in adults, both as detected by an FDA-approved test.
Alunbrig (brigatinib)
(brigatinib)Takeda Pharmaceuticals America, Inc.
Usage: ALUNBRIG is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as confirmed by an FDA-approved test.
Augtyro (repotrectinib)
(repotrectinib)E.R. Squibb & Sons, L.L.C.
Usage: AUGTYRO is indicated for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients aged 12 and older with locally advanced or metastatic solid tumors harboring NTRK gene fusions that have progressed after treatment or lack alternatives.
Balversa (erdafitinib)
(Erdafitinib)Janssen Products LP
Usage: BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma with FGFR3 genetic alterations, after disease progression on at least one prior systemic therapy. Use an FDA-approved companion diagnostic for patient selection. It's not recommended for those eligible for prior PD-1 or PD-L1 inhibitor therapy.
Bosulif (bosutinib)
(Bosutinib)Pfizer Laboratories Div Pfizer Inc
Usage: BOSULIF is indicated for the treatment of adult and pediatric patients (1 year and older) with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), either newly diagnosed or resistant/intolerant to prior therapy, as well as adult patients with accelerated or blast phase Ph+ CML.
Calquence (acalabrutinib)
(acalabrutinib)AstraZeneca Pharmaceuticals LP
Usage: CALQUENCE is indicated for adult patients with previously untreated or treated mantle cell lymphoma (MCL), those ineligible for autologous stem cell transplantation, and patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Cotellic (cobimetinib)
(COBIMETINIB)Genentech, Inc.
Usage: COTELLIC® is indicated for treating adult patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, in combination with vemurafenib, and as a single agent for adult patients with histiocytic neoplasms.
Erlotinib (erlotinib)
(Erlotinib)Cadila Healthcare Limited
Everolimus (everolimus)
(Everolimus)Ascend Laboratories, LLC
Usage: Everolimus tablets are indicated for the prevention of organ rejection in adult kidney transplant patients at low to moderate immunologic risk and in liver transplant patients, administered with specific immunosuppressants. Therapeutic drug monitoring is recommended. Safety has not been established for high-risk kidney recipients or in pediatric patients.
Fyarro (sirolimus)
(Sirolimus)Aadi Bioscience
Usage: FYARRO™ is indicated for treating adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).